Lyell Immunopharma (LYEL) News Today $0.70 +0.04 (+6.17%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.61%) As of 02/21/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Lyell Immunopharma (LYEL) to Release Earnings on WednesdayLyell Immunopharma (NASDAQ:LYEL) will be releasing earnings on Wednesday, February 26.February 19 at 4:44 AM | marketbeat.comLyell Immunopharma Announces Participation in Upcoming Investor ConferencesFebruary 18, 2025 | globenewswire.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stakeJanuary 31, 2025 | finance.yahoo.comLyell Immunopharma Faces Nasdaq delisting over share priceJanuary 25, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Lyell Immunopharma (LYEL) and Gilead Sciences (GILD)January 16, 2025 | markets.businessinsider.comLyell Immunopharma price target lowered to 60c from $1 at BofAJanuary 12, 2025 | markets.businessinsider.comLyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comBank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)January 7, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)December 24, 2024 | markets.businessinsider.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLCFmr LLC cut its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 62.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,024,583 shares of the company's stock after selling 1,708,879 shares during the quaDecember 16, 2024 | marketbeat.comLyell Immunopharma Inc Ordinary SharesDecember 12, 2024 | morningstar.comLyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual MeetingDecember 9, 2024 | globenewswire.comMitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market ChallengesNovember 13, 2024 | markets.businessinsider.comThe Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 ExpertsNovember 12, 2024 | benzinga.comHC Wainwright Reaffirms Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Tuesday.November 12, 2024 | marketbeat.comLyell Immunopharma reports Q3 net loss $44.6M vs. $50.9M last yearNovember 9, 2024 | markets.businessinsider.comLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024November 8, 2024 | markets.businessinsider.comLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | globenewswire.comLyell shares down as BofA double downgrades to SellNovember 1, 2024 | msn.comLyell Immunopharma’s Strategic Moves and Leadership ExpansionNovember 1, 2024 | markets.businessinsider.comLyell Immunopharma Completes Acquisition of ImmPACT BioOctober 31, 2024 | globenewswire.comLyell Immunopharma double downgraded to Underperform at BofA after reorgOctober 31, 2024 | markets.businessinsider.comLyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition StrategyOctober 31, 2024 | benzinga.comB of A Securities Downgrades Lyell Immunopharma (LYEL)October 31, 2024 | msn.comLyell cut to underperform by BofA, pipeline reorganization citedOctober 31, 2024 | msn.comBank of America Downgrades Lyell Immunopharma (NASDAQ:LYEL) to UnderperformBank of America downgraded shares of Lyell Immunopharma from a "buy" rating to an "underperform" rating and lowered their price target for the stock from $6.00 to $1.00 in a report on Wednesday.October 30, 2024 | marketbeat.comNeutral Rating for Lyell Immunopharma Amid Strategic Shifts and Competitive ChallengesOctober 29, 2024 | markets.businessinsider.comLyell Immunopharma (NASDAQ:LYEL) Rating Reiterated by HC WainwrightHC Wainwright restated a "neutral" rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Monday.October 28, 2024 | marketbeat.comLyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipelineOctober 25, 2024 | finance.yahoo.comLyell Immunopharma Acquires ImmPACT Bio to Enhance PipelineOctober 25, 2024 | markets.businessinsider.comLyell to acquire ImmPACT Bio, discontinue LYL797 and LYL845 programsOctober 25, 2024 | markets.businessinsider.comLyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer TreatmentsOctober 25, 2024 | marketwatch.comLyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell TherapiesOctober 24, 2024 | globenewswire.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Decreases By 19.4%Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 10,660,000 shares, a drop of 19.4% from the September 15th total of 13,220,000 shares. Currently, 9.4% of the company's shares are sold short. Based on an average trading volume of 667,100 shares, the days-to-cover ratio is presently 16.0 days.October 13, 2024 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comLyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingOctober 4, 2024 | globenewswire.comLyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy DaySeptember 24, 2024 | finance.yahoo.comLyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy DaySeptember 24, 2024 | globenewswire.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Position Trimmed by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA reduced its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 62.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 577,319 shares of the company's stock after selling 963,521 sharesSeptember 23, 2024 | marketbeat.comStudy finds ‘supercharging’ T cells with mitochondria enhances their antitumor activitySeptember 15, 2024 | msn.comLyell Immunopharma, Inc. (NASDAQ:LYEL) is WuXi AppTec Co. Ltd.'s 2nd Largest PositionWuXi AppTec Co. Ltd. lessened its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 6.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,682,156 shares of the company's stock after selling 498,522September 8, 2024 | marketbeat.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 7.9% in AugustLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a large drop in short interest in August. As of August 15th, there was short interest totalling 15,030,000 shares, a drop of 7.9% from the July 31st total of 16,320,000 shares. Currently, 13.3% of the company's stock are sold short. Based on an average daily volume of 945,800 shares, the days-to-cover ratio is currently 15.9 days.September 2, 2024 | marketbeat.com3 Penny Stocks to Buy With $500August 30, 2024 | 247wallst.comLyell Immunopharma Announces Participation in September Investor ConferencesAugust 28, 2024 | globenewswire.comRecent uptick might appease Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners after losing 32% over the past yearAugust 24, 2024 | finance.yahoo.comLyell Immunopharma, Inc. (LYEL)August 21, 2024 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)August 19, 2024 | markets.businessinsider.comLyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Beats Expectations By $0.02 EPSLyell Immunopharma (NASDAQ:LYEL - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 335,794.09% and a negative return on equity of 33.92%.August 11, 2024 | marketbeat.comLYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q2 2024August 8, 2024 | markets.businessinsider.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024August 7, 2024 | finance.yahoo.com Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Media Mentions By Week LYEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYEL News Sentiment▼0.000.60▲Average Medical News Sentiment LYEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYEL Articles This Week▼21▲LYEL Articles Average Week Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPT News SANA News LENZ News QURE News RLAY News TYRA News ANAB News KURA News CRMD News ABUS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYEL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
